Abiopharma

News list

BIENAIME JEAN JACQUES 🟢 acquired 1.0K shares of Keros Therapeutics, Inc. (KROS) at $11.70 Transaction Date: Apr 15, 2026 | Filing ID: 000005

Full text

News bot April 17, 2026, 8:15 p.m.
🔍 BIENAIME JEAN JACQUES (Executive)

Company: Keros Therapeutics, Inc. (KROS)

Report Date: 2026-04-15
Transaction Summary:
- Total transactions: 1
- Derivative instruments: 0
- Holdings reported: 0
- Total shares acquired: 1,000
Detailed Transactions and Holdings:
- Acquired 1,000 shares of Common Stock at $11.7 per share (Direct)
  Date: 2026-04-15 | Code: P | equity_swap_involved: 0 | shares_owned_after: 8,450.00 | transaction_form_type: 4 | Footnotes: F1, F2
Footnotes:
- F1: Shares were purchased pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025.
- F2: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.56 to $11.80 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.